Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 Case reports

Clinical Infectious Diseases

Volumn 47, Issue 3, 2008, Pages

  Gallagher, David P ^a,c   Kieran, Jennifer ^a   Sheehan, Gerard ^a,b   Lambert, John ^a,b   Mahon, Niall ^a   Mallon, Patrick W G ^a,b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NONE   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIAZEPAM; EMTRICITABINE; FLURAZEPAM; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; METHADONE; RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; CARDIOVERSION; CASE REPORT; COLLAPSE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART VENTRICLE TACHYCARDIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; MALE; PATIENT MONITORING; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TREATMENT OUTCOME;

ADULT; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TACHYCARDIA, VENTRICULAR;

EID: 47549110389     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/589869     Document Type: Article

References (10)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296:827-43.
2. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635-41.
3. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682-6.
4. Gil M, Sala M, Anguera I, et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003; 92:995-7.
5. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44:e67-8.
6. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866-74.
7. Owens RC Jr, Nolin TD. Reply to Chinello and Petrosillo (letter). Clin Infect Dis 2007; 44:1389-91.
8. Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006; 7:317-22.
9. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal." J Cardiovasc Electrophysiol 2006; 17:333-6.
10. Falconer M, Molloy D, Ingerhaug J, Barry M. Methadone induced torsade de pointes in a patient receiving antiretroviral therapy. Ir Med J 2007; 100:631-2.